Business Context and Reporting Period
Tenon Medical, Inc. (TNON) filed this Form 8-K on September 9, 2024, reporting a notification from The Nasdaq Stock Market regarding a failure to meet the Minimum Float Requirement. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Los Gatos, CA.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data disclosed relates to share counts following a 1-for-8 reverse stock split executed on September 6, 2024:
- Pre-split outstanding shares: 4,081,767
- Post-split outstanding shares: 510,221
- Publicly held shares (post-split): 490,364
- Minimum Float Requirement: 500,000 shares
Material Changes
The Company received a delisting notification from Nasdaq because its publicly held shares (490,364) fell below the required 500,000 threshold. This deficiency resulted directly from the 1-for-8 reverse stock split completed on September 6, 2024, which reduced the total share count.
Outlook, Management Commentary, and Risks
Compliance Plan: Nasdaq has granted the Company until October 24, 2024, to submit a specific plan to regain compliance. Management expects to achieve compliance in September 2024 through the consummation of a public offering of common stock under a previously filed Form S-1 (No. 333-281531).
Current Listing Status: The notification has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market.
Risks: Failure to regain compliance by the deadline or successfully execute the planned offering could result in delisting.
Investor Verification Checklist
- Verify the status and expected closing date of the public offering referenced in Form S-1 (No. 333-281531).
- Confirm whether the Company has submitted a compliance plan to Nasdaq by the October 24, 2024 deadline.
- Monitor the number of publicly held shares to ensure it exceeds the 500,000 threshold post-offering.
- Review subsequent filings for any updates on the reverse stock split or potential delisting proceedings.